Search details
1.
Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer.
Curr Oncol Rep
; 24(10): 1287-1298, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35575959
2.
Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis.
Int J Mol Sci
; 23(5)2022 Feb 25.
Article
in English
| MEDLINE | ID: mdl-35269713
3.
Cancer transcriptomic profiling from rapidly enriched circulating tumor cells.
Int J Cancer
; 146(10): 2845-2854, 2020 05 15.
Article
in English
| MEDLINE | ID: mdl-32037533
4.
Epigenetic plasticity potentiates a rapid cyclical shift to and from an aggressive cancer phenotype.
Int J Cancer
; 146(11): 3065-3076, 2020 06 01.
Article
in English
| MEDLINE | ID: mdl-32017074
5.
Liquid Biopsy in Prostate Cancer: Circulating Tumor Cells and Beyond.
Cancer Treat Res
; 175: 87-104, 2018.
Article
in English
| MEDLINE | ID: mdl-30168118
6.
Development and Application of Liquid Biopsies in Metastatic Prostate Cancer.
Curr Oncol Rep
; 20(4): 35, 2018 03 23.
Article
in English
| MEDLINE | ID: mdl-29572775
7.
AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth.
Prostate
; 76(6): 597-608, 2016 May.
Article
in English
| MEDLINE | ID: mdl-26771938
8.
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial.
Int J Cancer
; 136(8): 1856-62, 2015 Apr 15.
Article
in English
| MEDLINE | ID: mdl-25219358
9.
Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/ß-catenin/CBP pathway.
Int J Cancer
; 134(1): 43-54, 2014 Jan 01.
Article
in English
| MEDLINE | ID: mdl-23784558
10.
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
Lancet Oncol
; 14(9): 893-900, 2013 Aug.
Article
in English
| MEDLINE | ID: mdl-23871417
11.
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel.
Eur Urol
; 85(2): 171-176, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37085425
12.
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel.
Prostate Cancer Prostatic Dis
; 2024 Feb 29.
Article
in English
| MEDLINE | ID: mdl-38424319
13.
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
Clin Cancer Res
; 30(2): 444-449, 2024 01 17.
Article
in English
| MEDLINE | ID: mdl-37966367
14.
m6A epitranscriptome analysis reveals differentially methylated transcripts that drive early chemoresistance in bladder cancer.
NAR Cancer
; 5(4): zcad054, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-38023731
15.
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).
Eur Urol
; 84(3): 341-347, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37414705
16.
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.
Eur Urol Oncol
; 6(5): 516-524, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37087309
17.
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
J Clin Oncol
; 41(18): 3352-3362, 2023 06 20.
Article
in English
| MEDLINE | ID: mdl-36996380
18.
FOXC1 Binds Enhancers and Promotes Cisplatin Resistance in Bladder Cancer.
Cancers (Basel)
; 14(7)2022 Mar 28.
Article
in English
| MEDLINE | ID: mdl-35406487
19.
Bladder cancer cells shift rapidly and spontaneously to cisplatin-resistant oxidative phosphorylation that is trackable in real time.
Sci Rep
; 12(1): 5518, 2022 04 01.
Article
in English
| MEDLINE | ID: mdl-35365706
20.
External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer.
Mol Cancer Ther
; 21(12): 1857-1861, 2022 12 02.
Article
in English
| MEDLINE | ID: mdl-36198026